Siegmund et al., 2002 - Google Patents
Effect of levothyroxine administration on intestinal P‐glycoprotein expression: Consequences for drug dispositionSiegmund et al., 2002
- Document ID
- 13239158815646769094
- Author
- Siegmund W
- Altmannsberger S
- Paneitz A
- Hecker U
- Zschiesche M
- Franke G
- Meng W
- Warzok R
- Schroeder E
- Sperker B
- Terhaag B
- Cascorbi I
- Kroemer H
- Publication year
- Publication venue
- Clinical Pharmacology & Therapeutics
External Links
Snippet
Objective Thyroid function alters the pharmacokinetics of many drugs; one example is the cardiac glycoside digoxin. Because digoxin disposition is affected by intestinal expression of P‐glycoprotein, we hypothesized that thyroid hormones may regulate P‐glycoprotein and …
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter 0 title abstract description 86
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sakaeda et al. | MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects | |
| Siegmund et al. | Effect of levothyroxine administration on intestinal P‐glycoprotein expression: Consequences for drug disposition | |
| US11932676B2 (en) | Recombinant klotho proteins and compositions and methods involving same | |
| Wang et al. | OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine | |
| Wandel et al. | CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4* 1B 5′‐promoter region polymorphism | |
| Saxena et al. | Leptin as a novel profibrogenic cytokine in hepatic stellate cells: mitogenesis and inhibition of apoptosis mediated by extracellular regulated kinase (Erk) and Akt phosphorylation | |
| Gagliardi et al. | Corticosteroid-binding globulin: the clinical significance of altered levels and heritable mutations | |
| WO2017210607A1 (en) | Therapeutic recombinant klotho proteins and compositions and methods involving the same | |
| US5260200A (en) | Isolated DNA encoding an insulin receptor substrate | |
| JP2018526368A (en) | Treatment of Fabry disease in ERT naive patients and ERT experienced patients | |
| US20230107235A1 (en) | NOTCH3 Agonist Compositions and Methods for Treating Small Vessel Diseases | |
| Brenner et al. | P-glycoprotein function in the elderly | |
| JP6830458B2 (en) | Compositions and Methods for Detecting, Treating, and Preventing Diseases and Disorders | |
| Klein et al. | Elevation of serum insulin concentration during euglycemic hyperinsulinemic clamp studies leads to similar activation of insulin receptor kinase in skeletal muscle of subjects with and without NIDDM | |
| Chuang et al. | Sibling-based association study of the PPARγ2 Pro12Ala polymorphism and metabolic variables in Chinese and Japanese hypertension families: a SAPPHIRe study | |
| IL188288A (en) | Polypeptide having an activity of suppressing food intake and pharmaceutical compositions containing the same | |
| Morita et al. | MDR1 genotype-related duodenal absorption rate of digoxin in healthy Japanese subjects | |
| Boder et al. | Mechanistic interactions of uromodulin with the thick ascending limb: perspectives in physiology and hypertension | |
| Sheu et al. | Tumor necrosis factor [alpha]-238 and-308 polymorphisms do not associate with insulin resistance in hypertensive subjects | |
| US20050031605A1 (en) | Compositions and methods of treating diabetes | |
| Li et al. | Protective effects of erythropoietin on myocardial infarction in rats: the role of AMP-activated protein kinase signaling pathway | |
| WO2013022927A2 (en) | Treatment of uterine leiomyomata | |
| WO1992013083A1 (en) | Nucleic acid encoding insulin receptor substrate-1 (irs-1), irs-1 protein, diseases, therapy associated with the metabolism of irs-1 | |
| CN111050786A (en) | Modified fibroblast growth factor 21(FGF-21) for use in a method of treating non-alcoholic steatohepatitis (NASH) | |
| Ilag et al. | Reduced pancreatic polypeptide response to hypoglycemia and amylin response to arginine in subjects with a mutation in the HNF-4alpha/MODY1 gene. |